

OFFICE OF THE ASSISTANT SECRETARY FOR HEALTH

Room 713E, 200 Independence Avenue, SW

Washington, DC, 20201

tel (202) 401-7736

fax (202) 690-5432

fax t r a n s m i t t a l

to:

Kenneth Thorpe/Rose Chu

Jennifer

fax #:

703-941-3951

from:

Lisa Simpson, MB, BCh, MPH

date:

4/19/94

re:

Medical Foods

pages:

, including this cover sheet

NOTES: Ken, here is background for Rose et al at ARC. Let me know if you need anything else.

Call if you have any questions.

*Jen - I only attached Holly's
#s - the other are voluminous
pages of stuff -*

NOTE TO JENNIFER KLEIN, KEN THORPE, ROSE CHU**Medical Foods and Insurance Coverage**

- The primary inherited metabolic disorders are:
 - PKU - 1 / 10,000 to 1 / 25,000 live births (1990 CORN data is 1:13,000)*
 - Galactosemia - 1 / 42,000 LB (1990 CORN data)* to 1 in 80,000
 - Tyrosinemia - 1 / 20,000 to 1 / 160,000 (CORN data)* LB
 - Glutaric Acidemia - 1 / 30,000 [in Sweden] LB*
 - Homocystinuria - 1 / 50,000 to 1 / 155,000 LB (latter is 1990 CORN data)*
 - Biotinidase - 1 / 61,000 to 72,000 (1990 data from 14 states' screening progs.)*
 - Maple Syrup Urine Disease - 1 / 250,000 to 1 / 300,000 LB*
 - Methylmalonic Aciduria - 1 / 20,000 to 1 / 50,000 (1990 CORN data)* LB
- Using numbers provided by Holly Wolf (attached) there are between 972 and 1,389 live births each year with one of these conditions.
- PKU has been estimated to make up 1/4 of all inborn errors and has a patient population of about 15,000.
- PKU treatment programs are now recommending keeping children/adults with inherited metabolic disorders be kept on supplemental diets for LIFE.
- Medical foods or formulas are usually used to provide supplemental calories and nutrients to make up for the often very restrictive diets that these patients must follow in order to ensure that children grow and thrive.
- 1988 survey of state treatment programs for PKU and selected other inherited metabolic diseases showed:
 - family health insurance has grown as a source of coverage for families from 37% in 1982 to 56% in 1988;
 - discussions with treatment program staff in California reveal that they are usually able to get insurance coverage for formulas;
 - State health departments' children with special health care needs programs (Title V programs) also cover formula for lower income children, or when insurance denies.
- At least 14 States have mandated coverage for PKU. All of these include coverage of the medical food in their mandate.
- Attached are data from both Holly Wolf (PKU Network) and an analysis by one of the companies that produces these medical foods. It is not clear how accurate either of these estimates are but they should provide a range for estimation. The numbers provided by SHS are wholesale and could include a 10% to 150% markup for a retail price.

Children's PKU Network

10515 Vista Sorrento Pkwy.
San Diego, California 92121
Phone (619) 587-8421
Fax (619) 450-5034

Holly Howard Wolf
Founder and President

BOARD OF DIRECTORS

Wynn Berven
Debbie Broids
Rhonda Connolly
Brenda Delcambre
Michelle Binder Hall, R.N.
Timothy C. Howard
Jimmy D. Jackson
Richard Koch, M.D.
Tricia Louis
James F. Mulvaney, Jr.
Laurence M. Schreiber
Virginia Schuert, M.S., R.D.
Rick J. Schwering
David M. Swan

ADVISORY BOARD

Phyllis Adair, Dr.P.H.
Director of Nursing Services
Riverside Children's Hospital

Mary Amodeo, M.D.
Chief, Pediatric Clinic
New England Medical Center

Cunningham, M.D.
Chief, Genetic Diseases Branch
National Center of Human Genome Research

Maria E. Donnelly
Executive Director, PKU Project

Linda Gittling, M.S., R.D.
San Diego

Guthrie, Ph.D., M.D.
Professor, University of California
at Berkeley, School of Public Health

David Guy, Ph.D.
Executive Director, Research Institute
for Genetic Medicine

Kathy Jaw, R.N.
Director of Genetic Medicine
UCSD

Marilyn Kaufhold, M.D.
San Diego Center for Child Endocrine Services

Edward R.B. McCabe, M.D., Ph.D.
Chief, R.J. Children's Clinical Center
Texas Children's Hospital

F. Mulvaney, Sr., J.D.
Attorney at Law, San Diego

William Nyhan, M.D., Ph.D.
Chief, Division of Metabolic Diseases
UCSD School of Medicine

Laura Packer, J.D.
Attorney, Practice & Counsel, San Diego

Prince, Ph.D., R.D.
Attorney and Management Counsel
University of California at San Diego

Marylynne Rice-Abern, R.D.
Dept. of Pediatrics, UCSD School of Medicine

John E. Snyderman, M.D.
Chief, Pediatric Endocrine Center, N.Y.U.

Cristine M. Trehan, M.S., R.D.
Dept. of Pediatrics, University of Washington

Elizabeth Wang, M.S., R.D.
Director of Medical Nutrition
Child and Adolescent Center, Los Angeles

Marcy E. Wolf Ed.D.
Dir. of Special Programs, University of California

Steven Yaeger, M.Sc., R.D.
Chief Nutrition Specialist, San Diego Children's Hospital

FAX TRANSMITTAL

Asst. Secretary of Health
To: Office From: Holly H. Wolf

Reference: Medical Food
Txmt. Cast

Attn: Dr. Lisa Simpson Date: April 15, 1994
Senior Health Policy Analyst Time: _____

Fax: (202) 690 5432 # of Pages Sent: 5

Remarks: _____

Dear Dr. Simpson:

It was a pleasure speaking
with you yesterday. I apologize
for the delay.

First of next week I can supply
you with additional information
as needed. Please contact
Bobby Silverstein of Senator Tom Harkin's
office and Bill Schultz of Congressman
Waxman's as well as Faye Drummond
of Senate Finance Committee. I
think this would be a prudent thing to
keep all abreast of activities.

Look forward to working with you.

Sincerely,

P.S. I failed to include
Dr. Dunn and Dr. Marty Seig-Rice
both staff on Labor & Human Resources Committee
Holly H. Wolf
President, Founder

Children's PKU Network

A non-profit organization

10515 Vista Sorrento Pkwy.
San Diego, California 92121
Phone (619) 587-9421
Fax (619) 450-5034

Holly Howard Wolf
Founder and President

BOARD OF DIRECTORS

Wynn Berven
Debbie Broida
Rhonda Connolly
Brenda Delcambre
Michele Binder Hall, R.N.
Timothy C. Howard
Jimmy D. Jackson
Richard Koch, M.D.
Tricia Louis
James F. Mulvaney, Jr.
Laurence M. Schreiber
Virginia Schuett, M.S., R.D.
Rick J. Schwering
David M. Swan

ADVISORY BOARD

Phyllis Acosta, Dr.P.H.
Director of Nutrition Services
New York-Presbyterian

Mary Ampola, M.D.
Director, Metabolic Clinic
New England Medical Center

George Cunningham, M.D.
Chief, Genetic Diseases Branch
California Department of Health Services

Walter S. Denny
Neurologist, New York

Linda Gilliland, M.S., R.D.
San Diego

Robert Guille, Ph.D., M.D.
Professor of Pediatrics and
Neurology, University of Illinois

David Guy, Ph.D.
Principal Genetic Research Scientist
NIH, Bethesda, Maryland

Kathy Jew, R.N.
Director of Genetic Services
UCSF

Marlyn Kaufeld, M.D.
San Diego Center for Child Development Services

Edward R. McCabe, M.D., Ph.D.
Director, A.J. Kasper Clinic Center
Texas Children's Hospital

James F. Mulvaney, Sr., J.D.
Attorney at Law, San Diego

William Nyhan, M.D., Ph.D.
Chief, Division of Metabolic Diseases
UCSD School of Medicine

Laure Packer, J.D.
Director, Policy & Public Affairs, San Diego

Annie Prince, Ph.D., R.D.
Child Development and Rehabilitation Center
Children's Hospital, Los Angeles

Marilynne Rice-Asato, R.D.
Chief of Dietetics, UCSD School of Medicine

Salma E. Snyderman, M.D.
Director, Metabolic Diseases Center, UCSF

Cristine M. Trahms, M.S., R.D.
Chief of Dietetics, University of Washington

Elizabeth Wenz, M.S., R.D.
Director of Nutrition Services
Children's Hospital, Los Angeles

Nancy E. Wolf, Ed.D.
Dr. of Health & Human Services, University of Illinois

Steven Yannicelli, M.N.Sc., R.D.

April 14, 1994


To Whom It May Concern:

The following schedule lists some of the inborn errors of metabolism which are medically dependent upon medical foods for their optimum health and survival. Incidence of these diseases are generally low, ranging from 1 per 300,000 live births for maple syrup urine disease to 1 per 10-25,000 with phenylketonuria. Incidence and cost of treatment for a 40 year life span is included. Children and adults with these diseases cannot metabolize one or more amino acids, the building blocks of proteins. Untreated, these inherited diseases can lead to untimely death, dementia, and institutionalization costing society in excess of \$3,000,000 per affected over a lifetime.

These medical formulas provide up to 70% of the required nutriture for affected individuals, without treatment serious consequences will ensue. The modified phenylalanine product cost, which are supplemental to PKU's medical dietary treatment are included, however they are pending under F.D.A. review process for consideration as a medical food. Costs are based on 40% markup of wholesale prices of commercially available formulas.

These numbers are only estimates and should be regarded as such. For further questions, please do not hesitate to contact me at (619) 587-9421.

Sincerely,



Holly Howard Wolf
President

SUMMARY OF SELECTED INBORN ERRORS OF METABOLISM

<u>DISORDER</u>	<u>ANNUAL INCIDENCE</u>
-----------------	-------------------------

INBORN ERRORS OF AMINO ACID METABOLISM

Glutaric aciduria, type I (glutaryl-CoA dehydrogenase)	135 live births
Glutaric aciduria, type II (electron transfer flavoprotein or electron transfer flavoprotein ubiquinone oxidoreductase)	Unknown (rare)
Homocystinuria, nonresponsive	27-81 live births
3-Hydroxy-3-methylglutaric aciduria (3-hydroxy-3-methylglutaryl-CoA lyase)	Unknown (rare)
Isovaleric acidemia (isovaleryl-CoA dehydrogenase)	Unknown (rare)
Maple syrup urine disease branched- chain ketoacid dehydrogenase complex)	14-41 live births
3-Methylcrotonyl-glycinuria (3-methylcrotonyl-CoA carboxylase)	Unknown (rare)
3-Methylglutaconic aciduria (3-methylglutaconyl-CoA hydratase)	Unknown (rare)
Methylmalonic acidemia (cobalamin reductase; adenosyltransferase)	Unknown (rare)
Methylmalonic aciduria (methylmalonyl-CoA mutase or mutase)	203 live births
Phenylketonuria (PKU) (phenylalanine hydroxylase)	162-405 live births

cont. pg 2

PKU because of tetrahydrobiopterin deficiency (guanosine triphosphate cyclohydrolase; 6-pyruvoyl-tetrahydrobiopterin synthetase; dihydropteridine reductase) 16-41 live births

Propionic acidemia (propionyl-CoA Carboxylase) Unknown (rare)

Tyrosinemia type I (fumarylacetoacetate hydrolyase) 203 live births

Tyrosinemia type II (tyrosine aminotransferase) Unknown (rare)

INBORN ERRORS OF CARBOHYDRATE METABOLISM

Pyruvate dehydrogenase E1a or E1b < 16 live births

INBORN ERRORS OF MINERAL AND VITAMIN METABOLISM

Hypercalcemia (Williams syndrome) Unknown (rare)
idiopathic infantile hypercalcemia;
carbonic anhydrase II deficiency

INBORN ERRORS OF NITROGEN METABOLISM

N-Acetylglutamate synthetase deficiency Unknown (rare)

Argininemia (arginase deficiency) < 32 live births

Argininosuccinic aciduria (argininosuccinate lyase) 41-58 live births

Carbamyl phosphate synthetase deficiency 41-58 live births

Citrullinemia (argininosuccinate synthetase) 41-58 live births

Ornithine transcarbamylase deficiency 41-58 live births

Disease	Number of live births in U.S. with disease(a)	Number of individuals in U.S. with disease assuming 40 year life span	*Medical food treatment cost per person per year over a 40 year life span(b)	Medical food treatment cost in dollars per individual over 40 year life span	Number of individuals for all diseases
Phenylketonuria(PKU)	162-405	6480-16,200			
female	est.		\$4500-5000	\$180,000-200,000	\$29,1
male			\$5000-5625	\$200,000-225,000	91,12
Glutaric Aciduria	135	5,400			
female			\$4750-7500	\$190,000-300,000	\$25,65
male			\$5625-8750	\$225,000-350,000	47,250
Maple Syrup Urine Disease	13-41	520-1640			
female			\$3750-7500	\$150,000-300,000	\$1,950
male			\$4500-8750	\$180,000-350,000	14,350
Methylmalonic acidemia/ propionic acidemia	Unknown				
female			\$3500-7500	\$140,000-300,000	Unkno
male			\$4250-8750	\$170,000-350,000	
Homocystinuria/ Hypermethioninemia	Unknown				
female			\$3500-7500	\$140,000-300,000	Unkno
male			\$4000-8750	\$160,000-350,000	
					\$56,76
					152,72
					(\$56.7
					\$152.7

*Medical Foods- prescribed by a physician, these are commercially designed complete elemental ingredients specifically for the treatment of inborn errors of metabolism.

**Low phenylalanine dietary products -these modified products are supplemental to the medical dietary treatment and are recommended by a physician.

(a)Based upon census bureau estimates of total population
Selected Inborn Errors of Metabolism
of Metabolism

onal and
of treatment
individual
case

60,000-
5,000

1,000-
000

00-
10

LYNN SCHENK
49TH DISTRICT
CALIFORNIA



COMMITTEE ON ENERGY AND COMMERCE
TELECOMMUNICATIONS AND FINANCE
TRANSPORTATION AND HAZARDOUS MATERIALS

COMMITTEE ON MERCHANT MARINE AND
FISHERIES
MERCHANT MARINE
COAST GUARD AND NAVIGATION
OCEANOGRAPHY, THE GULF OF MEXICO, AND
THE OUTER CONTINENTAL SHELF

Congress of the United States
House of Representatives
Washington, D.C. 20515
FAX COVER SHEET

WASHINGTON OFFICE:

315 CANNON HOUSE OFFICE BUILDING
WASHINGTON, D.C. 20515
(202) 225-2040

DISTRICT OFFICES:

3900 FIFTH AVENUE, SUITE 200
SAN DIEGO, CA 92103
(619) 291-1430

825 IMPERIAL BEACH BOULEVARD
IMPERIAL BEACH, CA 91932
(619) 291-1430

TO: Jennifer Klein
WITH: _____
TIME: _____ DATE: _____
FAX NUMBER: 456 2878
TOTAL PAGES(INCLUDING COVER): 6

FROM THE DESK OF:

___ Congresswoman Lynn Schenk
___ Kerry Abelson
___ William Bold
___ Fran Callanan
___ Jonathan Correa
___ Joel Ginsburg

___ Suzanne Hassett
X ___ Alan Keller
___ Rochelle Roseman
___ George Wilson
___ Glynnis Vaughan

COMMENTS: _____

public/jonathan/fax

If you have any questions/problems concerning this transmission, please contact the Washington, D.C. Office at (202) 225-2040.

FAX # for Washington, D.C. Office: (202) 225-2042
FAX # for District Office: (619) 291-8956

Children's PKU Network

A non-profit organization

10515 Vista Sorrento Pkwy.
San Diego, California 92121
Phone (619) 587-9421
Fax (619) 450-5034

Holly Howard Wolf
Founder and President

BOARD OF DIRECTORS

Wynn Berven
Debbie Broda
Rhonda Connolly
Brenda Delcambre
Michele Binder Hall, R.N.
Timothy C. Howard
Jimmy D. Jackson
Richard Koch, M.D.
Tricia Louis
James F. Mulvaney, Jr.
Laurence M. Schreiber
Virginia Schuett, M.S., R.D.
Rick J. Schwenng
David M. Swan

ADVISORY BOARD

Phyllis Acosta, Dr.P.H.
Director of Nutrition Services
Raja Ladd Medical
Mary Ampola, M.D.
Director, Pediatric Clinic
Raja Ladd Medical Center
George Cunningham, M.D.
Chief, Genetic Disease Program
Children's Clinic of Health Services
Marie S. Donnelly
Nutritionist PKU Center
Linda Gilliland, M.S., R.D.
San Diego
Robert Guthrie, Ph.D., M.D.
Professor Emeritus of Pediatrics and
Metabolic Unit at University of Buffalo
David Guy, Ph.D.
Principal Clinical Research Scientist
West Jefferson Hospital
Kathy Jew, R.N.
Director of Genetics, Pediatrics
UCSD
Marilyn Kaufhold, M.D.
San Diego Children's Clinic Pediatric Services
Edward R.B. McCabe, M.D., Ph.D.
Director, R.J. Nagley Clinical Center
Texas Children's Hospital
James F. Mulvaney, Sr., J.D.
Attorney at Law, San Diego
William Nyhan, M.D., Ph.D.
Chief, Division of Genetics in Pediatrics
UCSD San Diego
Laura Packer, J.D.
Attorney, Foster & Wilson, San Diego
Annie Ponce, Ph.D., R.D.
Child Development and Rehabilitation Center
Oregon Health Sciences University
Marilynne Rice-Asaro, R.D.
Dept. of Pediatrics, UCSD School of Medicine
Selma E. Shyderman, M.D.
Director, Metabolic Disease Center, HCU
Christine M. Trahms, M.S., R.D.
Dept. of Pediatrics, University of Washington
Elizabeth Wenz, M.S., R.D.
Division of Medical Genetics
Children's Hospital of Los Angeles
Nancy E. Wolf Ed.D.
Dir. of Special Health Services, Riverside State U & D
Steven Yannicelli, M.M.Sc., R.D.
Chief, Pediatric Nutrition, Raja Ladd Medical

April 14, 1994


To Whom It May Concern:

The following schedule lists some of the inborn errors of metabolism which are medically dependent upon medical foods for their optimum health and survival. Incidence of these diseases are generally low, ranging from 1 per 300,000 live births for maple syrup urine disease to 1 per 10-25,000 with phenylketonuria. Incidence and cost of treatment for a 40 year life span is included. Children and adults with these diseases cannot metabolize one or more amino acids, the building blocks of proteins. Untreated, these inherited diseases can lead to untimely death, dementia, and institutionalization costing society in excess of \$3,000,000 per affected over a lifetime.

These medical formulas provide up to 70% of the required nutriture for affected individuals, without treatment serious consequences will ensue. The modified phenylalanine product cost, which are supplemental to PKU's medical dietary treatment are included, however they are pending under F.D.A. review process for consideration as a medical food. Costs are based on 40% markup of wholesale prices of commercially available formulas.

These numbers are only estimates and should be regarded as such. For further questions, please do not hesitate to contact me at (619) 587-9421.

Sincerely,


Holly Howard Wolf
President

SUMMARY OF SELECTED INBORN ERRORS OF METABOLISM

DISORDER

ANNUAL INCIDENCE

INBORN ERRORS OF AMINO ACID METABOLISM

Glutaric aciduria, type I (glutaryl-CoA dehydrogenase)	135 live births
Glutaric aciduria, type II (electron transfer flavoprotein or electron transfer flavoprotein ubiquinone oxidoreductase)	Unknown (rare)
Homocystinuria, nonresponsive	27-81 live births
3-Hydroxy-3-methylglutaric aciduria (3-hydroxy-3-methylglutaryl-CoA lyase)	Unknown (rare)
Isovaleric acidemia (isovaleryl-CoA dehydrogenase)	Unknown (rare)
Maple syrup urine disease branched- chain ketoacid dehydrogenase complex)	14-41 live births
3-Methylcrotonyl-glycinuria (3-methylcrotonyl-CoA carboxylase)	Unknown (rare)
3-Methylglutaconic aciduria (3-methylglutaconyl-CoA hydratase)	Unknown (rare)
Methylmalonic acidemia (cobalamin reductase; adenosyltransferase)	Unknown (rare)
Methylmalonic aciduria (methylmalonyl-CoA mutase or mutase)	203 live births
Phenylketonuria (PKU) (phenylalanine hydroxylase)	162-405 live births

cont. pg 2

PKU because of tetrahydrobiopterin deficiency (guanosine triphosphate cyclohydrolase; 6-pyruvoyl-tetrahydrobiopterin synthetase; dihydropteridine reductase)	16-41 live births
--	-------------------

Propionic acidemia (propionyl-CoA Carboxylase)	Unknown (rare)
--	----------------

Tyrosinemia type I (fumarylacetoacetate hydrolyase)	203 live births
---	-----------------

Tyrosinemia type II (tyrosine aminotransferase)	Unknown (rare)
---	----------------

INBORN ERRORS OF CARBOHYDRATE METABOLISM

Pyruvate dehydrogenase E1a or E1b	< 16 live births
-----------------------------------	------------------

INBORN ERRORS OF MINERAL AND VITAMIN METABOLISM

Hypercalcemia (Williams syndrome) idiopathic infantile hypercalcemia; carbonic anhydrase II deficiency	Unknown (rare)
--	----------------

INBORN ERRORS OF NITROGEN METABOLISM

N-Acetylglutamate synthetase deficiency	Unknown (rare)
---	----------------

Argininemia (arginase deficiency)	< 32 live births
-----------------------------------	------------------

Argininosuccinic aciduria (argininosuccinate lyase)	41-58 live births
---	-------------------

Carbamyl phosphate synthetase deficiency	41-58 live births
--	-------------------

Citrullinemia (argininosuccinate synthetase)	41-58 live births
--	-------------------

Ornithine transcarbamylase deficiency	41-58 live births
---------------------------------------	-------------------

Disease	Number of live births in U.S. with disease(a)	Number of individuals in U.S. with disease assuming 40 year life span	*Medical food treatment cost per person per year over a 40 year life span(b)	Medical food treatment cost in dollars per individual over 40 year life span	National annual medical food treatment cost for all individuals with disease	Additional cost of modified low phenylalanine dietary products per year per person
Phenylketonuria(PKU) female male	162-405 est.	6480-16,200	\$4500-5000 \$5000-5625	\$180,000-200,000 \$200,000-225,000	\$29,160,000- 91,125,000	\$2700
Glyutaric Aciduria female male	135	5,400	\$4750-7500 \$5625-8750	\$190,000-300,000 \$225,000-350,000	\$25,650,000- 47,250,000	
Maple Syrup Urine Disease female male	13-41	520-1640	\$3750-7500 \$4500-8750	\$150,000-300,000 \$180,000-350,000	\$1,950,000- 14,350,000	
Methylmalonic acidemia/ propionic acidemia female male	Unknown		\$3500-7500 \$4250-8750	\$140,000-300,000 \$170,000-350,000	Unknown	
Homocystinuria/ Hypermethioninemia female male	Unknown		\$3500-7500 \$4000-8750	\$140,000-300,000 \$160,000-350,000	Unknown	
					\$56,760,000- 152,725,000 (\$56.7 million- \$152.7 million)	

*Medical Foods- prescribed by a physician, these are commercially designed complete elemental ingredients specifically for the treatment of inborn errors of metabolism.

**Low phenylalanine dietary products -these modified products are supplemental to the medical dietary treatment and are recommended by a physician.

(a)Based upon census bureau estimates of total live births for 1993 and "Summary of Selected Inborn Errors of Metabolism" from *A Practitioner's Guide to Selected Inborn Errors of Metabolism*, 1992 Ross Laboratories
1993 total live births were estimated at 2,700,000 for the eight months through August, 1993. This estimate is extrapolated to estimate total 1993 live births at 4,050,000

(b) Cost estimates extrapolated from Scientific Hospital Supplies, Inc. cost comparison report.

Continuation of chart

Disease	Total annual cost of ••low phenylalanine dietary products for all U.S. individuals with disease	Total annual medical food treatment and low phenyl- alanine dietary product cost over 40 year life span
PKU		
female		
male	\$17,496,000- \$43,740,000	\$46,656,000- 134,865,000
Glutaric Aciduria		
female		
male		
Maple Syrup Urine Disease		
female		
male		
Methylmalonic acidemia/ propionic acidemia		
female		
male		
Homocystinuria		
Hypermethioninemia		
female		
male		
		<u>\$74,256,000-</u> 196,465,000 (\$74 million - \$196 million)

Medical Foods and Insurance Coverage

- The primary inherited metabolic disorders are:
 - PKU - 1 in 15,000
 - Galactosemia - 1 in 20,000
 - Maple Syrup Urine Disease - 1 in
 - Homocystinuria - 1 in
 - Biotinidase Deficiency -
- PKU treatment programs are now recommending keeping children/adults with inherited metabolic disorders be kept on supplemental diets for LIFE.
- Medical foods or formulas are usually used to provide supplemental calories and nutrients to make up for the often very restrictive diets that these patients must follow in order to ensure that children grow and thrive.
- 1988 survey of state treatment programs for PKU and selected other inherited metabolic diseases showed:
 - family health insurance has grown as a source of coverage for families from 37% in 1982 to 56% in 1988;
 - discussions with treatment program staff in California reveal that they are usually able to get insurance coverage for formulas;
 - State health departments' children with special health care needs programs (Title V programs) also cover formula for lower income children, or when insurance denies.
- At least 5 States have mandated coverage for PKU: AK, MA, MT, MN, WA. All of these include coverage of the medical food in their mandate.
- A recent study by Scientific Hospital Supplies entitled "*Comprehensive Pricing Analysis for Metabolic Disorders Formulas*" showed that formulas for PKU cost about:
 - \$1,300 per year for an infant
 - between \$2,800 and \$3,800 per year for grade school through teen years
 - about \$3,500 for children over 19.

Other formulas tend to cost more but are less prevalent.

FORMULAS FOR TREATMENT OF INHERITED METABOLIC DISEASES

Formulas used in the treatment of inherited metabolic diseases are very expensive, and a large burden for families to bear alone. Table 2 (page 6) shows that state health departments are the sole source or a major source of formula funding for 52 of the 112 programs (46%, compared to 55% of programs in the 1982 survey). Family health insurance has become a more significant source of funding over the past 6 years, however. Fifty-six percent of programs now utilize family health insurance as one source of funding, compared to 37% in 1982. It was listed as the major source of support by 17% of the programs compared to 10% in 1982.

Programs are also finding the need to utilize more different sources of support for formula funding. Twenty-one percent of programs used only one source in this survey (Figure 2), compared to 36% in 1982.

FIGURE 2

PERCENT OF PROGRAMS UTILIZING ONE, OR MULTIPLE SOURCES OF FORMULA FUNDING




TABLE 2
SOURCES OF FUNDING FOR FORMULAS USED IN
TREATMENT OF INHERITED METABOLIC DISEASES

SOURCE	Number of programs	Sole source	Major, not sole source
State Health Department	69	19*	33
Family Health Insurance	62	0	20
WIC Program	51	0	4
Crippled Childrens' Program	47	2	13
Families	40	1	2
MediCal/Medicaid	11	0	0
Military	5	0	0
Champus	4	0	0
Genetically Handicapped Persons Prog.	3	0	1
Title XIX	1	0	0
Childrens' Medical Services	1	0	0
Child Welfare	1	0	0

* Programs located in 11 states.

PKU DIET POLICIES

Program policies regarding PKU diet maintenance, as reported by the 105 clinics treating PKU, are described in Table 4. The majority of programs now recommend indefinite continuation of diet; most programs individualize their approach, however, considering the option of liberalizing or discontinuing diet in special circumstances.

In this survey 61% of programs reported that their policy is to recommend indefinite continuation of diet for males; 77% reported this as their recommendation for females. In the 1978 survey, 23% of programs recommended indefinite continuation of diet for males and 42% had this policy for females. A greater number of programs recommend indefinite continuation of diet for females than for males, reflecting concern over the need for females with PKU to maintain strict diet during pregnancy.

In the past 5 years, 29 programs reported that their policy for diet maintenance has changed, all becoming more conservative. Nineteen programs reported increasing the age at which either diet discontinuation or diet liberalization is allowed. Eleven programs reported encouraging more strict control of blood phenylalanine levels. One program reported more regular follow-up of males with PKU. Four programs reported that they were considering changing their diet maintenance policy to a more conservative one.

Of those programs recommending indefinite continuation of diet, 9 sanctioned higher blood phenylalanine levels for "older" children (desired upper limit ranging from 10 to 18 mg/dl). Two programs allowing the option of discontinuing diet at a specified age also allowed higher blood phenylalanine levels in "older" children (desired upper limit 12 or 15 mg/dl).

Definitions of "strict" diet were variable (see Table 5), as were definitions of "liberal" diet (Table 6), the age considered for diet liberalization (Table 7), and the age diet discontinuation is considered by programs allowing it (Table 8).

The mean age considered for diet "liberalization" for this survey was 10.4 years for males and 8.9 years for females, with a combined mean of 9.8 years. This compares to a combined male-female mean of 7.8 years in the 1982 survey.

The mean age considered for diet discontinuation for those clinics allowing it was 13.4 years for males and 12.4 years for females, with a combined mean of 12.7 years. This compares to a combined male-female mean of 7.5 years in the 1982 survey.

Overall policies for maintenance of the PKU diet have become increasingly conservative in the decade since the first survey in 1978 was done, when nearly one-half of the programs reported recommending diet discontinuation at ages ranging from 3 to 10 years.

TABLE 4
PKU DIET POLICIES

DIET POLICY	NUMBER OF PROGRAMS	
	For Males	For Females
Strict diet indefinitely	66	82
Strict diet until a specified age, then liberalized indefinitely	16	9
Strict diet until a specified age, then allow option of discontinuing	15	6
No policy	6	6
Policy unknown	2	2
TOTAL*	105	105

* Seven of the 112 identified programs treat only inherited metabolic diseases other than PKU.

Amendment

Amend Section 2001 (b) (5) (B), to read as follows (added language is underlined):

"(B) Not later than January 1, 1996, (and periodically thereafter), the Secretary shall publish a list of the drugs and indications for such drugs, that are covered home infusion drugs, with respect to which home infusion drug therapy may be provided under this title. The Secretary shall also establish by regulation not later than January 1, 1996 the circumstances and conditions where the provisions of oral medical foods (as defined in 21 U.S.C. 360 ee(b)(3)) is medically appropriate and cost effective."